ALXN Alexion Pharmaceuticals, Inc.

Price (delayed)

$102.97

Market cap

$22.57B

P/E Ratio

27.31

Dividend/share

N/A

EPS

$3.77

Enterprise value

$22.35B

Sector: Healthcare
Industry: Biotechnology
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA.

Highlights

ALXN's revenue is up by 23% year-on-year and by 4.6% since the previous quarter
The company's gross profit rose by 23% YoY and by 4% QoQ
ALXN's price to earnings (P/E) is 73% lower than its 5-year quarterly average of 100.4 but 73% higher than its last 4 quarters average of 15.8
Alexion Pharmaceuticals's equity has decreased by 11% from the previous quarter but it has increased by 3.2% YoY
The EPS has dropped by 65% since the previous quarter and by 37% year-on-year
ALXN's net income has dropped by 64% since the previous quarter and by 37% year-on-year

Key stats

What are the main financial stats of ALXN
Market
Shares outstanding
219.17M
Market cap
$22.57B
Enterprise value
$22.35B
Valuations
Price to earnings (P/E)
27.31
Price to book (P/B)
2.17
Price to sales (P/S)
4.1
EV/EBIT
41.54
EV/EBITDA
24.83
EV/Sales
4.04
Earnings
Revenue
$5.54B
EBIT
$538M
EBITDA
$900.2M
Free cash flow
$2.37B
Per share
EPS
$3.77
Free cash flow per share
$10.72
Book value per share
$47.51
Revenue per share
$25.1
TBVPS
$43.37
Balance sheet
Total assets
$16.7B
Total liabilities
$6.21B
Debt
$2.61B
Equity
$10.49B
Working capital
$4.25B
Liquidity
Debt to equity
0.25
Current ratio
4.79
Quick ratio
3.77
Net debt/EBITDA
-0.24
Margins
EBITDA margin
16.3%
Gross margin
91.6%
Net margin
15.3%
Operating margin
8.2%
Efficiency
Return on assets
5%
Return on equity
7.7%
Return on invested capital
7.2%
Return on capital employed
3.5%
Return on sales
9.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALXN stock price

How has the Alexion Pharmaceuticals stock price performed over time

Financial performance

How have Alexion Pharmaceuticals's revenue and profit performed over time
Revenue
$5.54B
Gross profit
$5.07B
Operating income
$452.1M
Net income
$846.1M
Gross margin
91.6%
Net margin
15.3%
ALXN's operating margin has dropped by 82% since the previous quarter and by 75% year-on-year
The operating income has plunged by 81% from the previous quarter and by 70% YoY
The net margin has shrunk by 66% QoQ and by 48% YoY
ALXN's net income has dropped by 64% since the previous quarter and by 37% year-on-year

Valuation

What is Alexion Pharmaceuticals stock price valuation
P/E
27.31
P/B
2.17
P/S
4.1
EV/EBIT
41.54
EV/EBITDA
24.83
EV/Sales
4.04
ALXN's price to earnings (P/E) is 73% lower than its 5-year quarterly average of 100.4 but 73% higher than its last 4 quarters average of 15.8
The EPS has dropped by 65% since the previous quarter and by 37% year-on-year
ALXN's P/B is 30% below its 5-year quarterly average of 3.1 but 3.3% above its last 4 quarters average of 2.1
Alexion Pharmaceuticals's equity has decreased by 11% from the previous quarter but it has increased by 3.2% YoY
ALXN's P/S is 49% below its 5-year quarterly average of 8.0 and 7% below its last 4 quarters average of 4.4
ALXN's revenue is up by 23% year-on-year and by 4.6% since the previous quarter

Efficiency

How efficient is Alexion Pharmaceuticals business performance
Alexion Pharmaceuticals's return on invested capital has shrunk by 79% QoQ and by 71% YoY
The ROS has dropped by 78% since the previous quarter and by 70% year-on-year
Alexion Pharmaceuticals's ROA has plunged by 66% from the previous quarter and by 47% YoY
Alexion Pharmaceuticals's ROE has plunged by 65% from the previous quarter and by 45% YoY

Dividends

What is ALXN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALXN.

Financial health

How did Alexion Pharmaceuticals financials performed over time
ALXN's total assets is 169% higher than its total liabilities
ALXN's total liabilities is up by 41% year-on-year but it is down by 2.9% since the previous quarter
The company's quick ratio rose by 21% YoY and by 14% QoQ
The debt is 75% lower than the equity
Alexion Pharmaceuticals's debt to equity has increased by 14% from the previous quarter but it has decreased by 7% YoY
Alexion Pharmaceuticals's equity has decreased by 11% from the previous quarter but it has increased by 3.2% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.